Sign-up to Receive
Our Latest Insights

CURE
VanEck Genomics and Healthcare Innovators UCITS ETF

Fund Description

Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.

  • Invest in genomics companies developing new ways to treat health problems such as genetic conditions, cancer and conditions related to ageing
  • Gain exposure to digital health services providers – delivering easy access to doctors, physiotherapists, nurses and pharmacists
  • Pure-play exposure to companies earning at least half their revenues from genomics- or e-healthcare-related industries
  • Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco


Risk: You may lose money up to the total loss of your investment due to the Main Risk Factors such as Equity Market Risk and Industry Concentration Risk described below in the KID and in the sales prospectus. Evolving of the market not guaranteed.



Underlying Index

MVIS® Global Future Healthcare ESG Index (MVFHCTR)

Fund Details
 

  • Fund Ticker

    CURE

  • Management Company

    VanEck Asset Management B.V.

  • Custodian

    State Street Custodial Services (Ireland) Limited

  • Domicile

    Ireland

  • UCITS Compliant

    Yes

  • Index Ticker

    MVFHCTR

  • Index Provider

    MarketVector Indexes

  • Rebalance Frequency

    Semi-Annually
1The "Net Asset Value" (NAV) of all ETFs is determined at the close of each business day, and represents the value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. Investors should not expect to buy or sell ETF shares at NAV.

2The date the fund was launched prior to quotation on the stock exchange.

 
as of 31 Jan 2023

  • NAV1

    21.82

  • Shares Outstanding

    310,000

  • Number of Holdings

    57

  • Base Currency

    USD

  • Net Assets

    $6.8M

  • Product Structure

    Physical (Full Replication)

  • Income Treatment

    Reinvestment

  • Distribution Frequency

    None

  • Total Expense Ratio

    0.35%

  • SFDR Classification

    Article 8
  • Fact Sheet
  • Fund Holiday Calendar

Trading Information as of 31 Jan 2023

Deutsche
Börse
EUR
Exchange Ticker CURE
ISIN IE000B9PQW54
SEDOL BNG7JX1
Bloomberg CURE GY
Reuters (RIC) CURE.DE
Valor 121031038
Bloomberg iNAV CUREUSIV
Reuters iNAV CUREINAV=SOLA
WKN A3DSGJ
Trading Currency EUR
Last Traded Price
Day's Move
Volume
30 Day Volume --
VWAP Volume

NAVs as of 31 Jan 2023

Base
Currency 		NAV Daily
Change
NAV 		YTD
Change
NAV 		NAV Price
History 		Total
Expense
Ratio
CURE USD $21.82 $0.20 / +0.91% +4.06%
0.35

Performance History* (%)

View All ETFs View All Indices
  1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR ETF INCEPTION
MVFHCTR (Index) -4.19 8.94 -24.99 -24.99 -- -- -- 4.11
  1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR ETF INCEPTION
MVFHCTR (Index) -4.19 8.94 -24.99 -24.99 -- -- -- 4.11
  2018 2019 2020 2021 2022
MVFHCTR (Index) -- -- -- -- -24.99

Past performance does not predict future returns.

ETF returns not available if there is less than one year’s performance data.

*Periods greater than one year are annualised.

Investing is subject to risk, including the possible loss of principal. You must read the Prospectus and KID before investing, which are available at the Document section of the fund on www.vaneck.com.

ETF performance: Current performance may be lower or higher than average annual returns shown. Discrete performance shows 12-month performance for each of the last 10 years where available. E.g. '1st year' shows the most recent of these 12-month periods and '2nd year' shows the previous 12 month period and so on.

Performance data for the Irish domiciled ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply.

Returns may increase or decrease as a result of currency fluctuations.

Index performance: Performance quoted represents past performance of the underlying Index. An index performance is not illustrative of the Product's performance. It is not possible to invest directly in an index: indices are not securities in which investments can be made.
For more information on the Index performance, please consult the Index Provider´s website.

MVIS® Global Future Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH (“MarketVector”), Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Genomics and Healthcare Innovators UCITS ETFis not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the Fund.

Market Makers

Top 10 Holdings (%) as of 31 Dec 2022 View All Holdings »

Total Holdings: 56
Swipe<br>to view <br> full data
Holding Name
Ticker
 Shares Market Value
(USD) 		% of Net
Assets
MODERNA INC MRNA US 3,022 542,812 8.35
VERTEX PHARMACEUTICALS INC VRTX US 1,703 491,792 7.57
REGENERON PHARMACEUTICALS INC REGN US 619 446,602 6.87
DEXCOM INC DXCM US 3,728 422,159 6.49
ILLUMINA INC ILMN US 1,946 393,481 6.05
BIONTECH SE BNTX US 2,287 343,553 5.28
VEEVA SYSTEMS INC VEEV US 2,045 330,022 5.08
ALNYLAM PHARMACEUTICALS INC ALNY US 1,315 312,510 4.81
M3 INC 2413 JP 9,900 268,462 4.13
JD HEALTH INTERNATIONAL INC 6618 HK 27,050 247,281 3.80
Top 10 Total (%) 58.43
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 31 Dec 2022

  • Country

    % of Net Assets
  • ■

    United States

    78.81
  • ■

    China

    7.29
  • ■

    Germany

    5.89
  • ■

    Japan

    4.13
  • ■

    United Kingdom

    1.62
  • ■

    Switzerland

    0.99
  • ■

    Australia

    0.77
  • ■

    Sweden

    0.50
  • ■

    Netherlands

    0.20
  • ■

    Other/Cash

    -0.19

Sector Weightings (%) as of 31 Dec 2022

  • Sector

    % of Net Assets
  • ■

    Health Care

    93.8
  • ■

    Consumer Discretionary

    5.9
  • ■

    Materials

    0.2
  • ■

    Consumer Staples

    0.2
  • ■

    Other/Cash

    -0.2

Technology

Sustainable

Crypto

Metal

Real Estate

Dividend

Discover more ETFs

More ETFs

 Important Disclosure           

This website is for informational/advertisement purposes only.

Information contained in this website does not constitute any legal or investment advice. This website does not constitute an offer to sell or solicitation to buy any security, including shares of any investment fund promoted on this website and other financial instrument, products or services sponsored by any VanEck affiliates ("VanEck").

VanEck constructs and issues the investment funds but does not give any financial advice to private investors or accept client funds. VanEck provides financial services (e.g. financial advice) only to professional clients according to the detailed definition in the Terms and Conditions of this website. For questions regarding investing or trading please contact your advisor, brokerage or bank. If you have technical questions regarding our investment funds, please contact us.

An investment in the promoted investment funds may only be made based on the investment fund’s official sales prospectus, the relevant supplement and KID and will be subject to the terms and conditions contained therein.

You can lose money by investing in the Funds. The value of the investments may go up or down and the investor may not get back the amount invested. Past performance is not a guide to future performance and should not be the sole factor of consideration when selecting a product. Any investment in a fund should be part of an overall investment program, not a complete program. An investor should consider investment objectives, risks, charges, and expenses of the investment carefully before investing.

Investment fund investing involves risk, including possible loss of principal. Investors should consult the prospectus and key information document ("KID") before subscribing to any fund. The prospectus, the key information documents and the financial reports can be obtained free of charge from this website and upon request from the funds’ registered office and the offices of all local information agents. The documents, except for KIDs, are only available in English and certain other languages as applicable.

Performance data for the Irish domiciled funds is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply. Performance data for the Dutch domiciled ETFs include income distributions gross of Dutch withholding tax, net of fees and assume that the Dutch dividend withholding tax levied from the dividend payment of the ETF will be deducted or reclaimed with the Dutch tax authority and is reinvested. Different investor types and investors from other jurisdictions may not be able to achieve the same level of performance due to their tax status and local tax rules. Brokerage or transaction fees will apply. The Dutch domiciled ETFs use a gross reinvestment index. Please note that the performance includes income distributions gross of Dutch withholding tax because Dutch investors deduct or reclaim the 15% Dutch withholding tax levied. Different investor types and investors from other jurisdictions may not be able to achieve the same level of performance due to their tax status and local tax rules. For more information please be referred to the respective fund’s performance section on this website.

The sales prospectus and KID contain this and other information. Please read the sales prospectus and KID carefully before investing.

Not Insured — No Bank Guarantee — May Lose Value

Web Access Notice: VanEck is committed to ensuring accessibility of its website for investors and potential investors, including those with disabilities. If you have difficulty accessing any feature or functionality on the VanEck website, please feel free to email us at info@vaneck.com for assistance.

©2023 VanEck®, VanEck Access the opportunities® and the stylized VanEck® design are trademarks of Van Eck Associates Corp.